NASDAQ:ENDP - Endo International Stock Price, Price Target & More

$5.65 +0.13 (+2.36 %)
(As of 04/24/2018 02:19 PM ET)
Previous Close$5.52
Today's Range$5.53 - $5.73
52-Week Range$5.27 - $14.15
Volume1.54 million shs
Average Volume5.49 million shs
Market Capitalization$1.23 billion
P/E Ratio1.47
Dividend YieldN/A
Beta0.38

About Endo International (NASDAQ:ENDP)

Endo International logoEndo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The U.S. Branded Pharmaceuticals segment provides XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's diseases; SUPPRELIN LA for central precocious puberty treatment; TESTOPEL, a long-acting implantable pellet for the treatment of central precocious puberty; NASCOBAL, a nasal spray to treat vitamin B12 deficiency; and AVEED for the treatment of hypogonadism. This segment also offers pain management products, such as PERCOCET, VOLTAREN Gel, and LIDODERM; TESTIM Gel for the treatment of endogenous testosterone; and FORTESTA Gel for hypogonadism treatment. The International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Receive ENDP News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ENDP
CUSIP29264F20
Phone011-353-1268-2000

Debt

Debt-to-Equity Ratio17.00%
Current Ratio1.02%
Quick Ratio0.85%

Price-To-Earnings

Trailing P/E Ratio1.47
Forward P/E Ratio2.42
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.47 billion
Price / Sales0.36
Cash Flow$8.5606 per share
Price / Cash0.66
Book Value$2.17 per share
Price / Book2.60

Profitability

EPS (Most Recent Fiscal Year)$3.84
Net Income$-2,035,430,000.00
Net Margins-58.68%
Return on Equity81.03%
Return on Assets7.02%

Miscellaneous

Employees3,039
Outstanding Shares223,340,000

How to Become a New Pot Stock Millionaire

Endo International (NASDAQ:ENDP) Frequently Asked Questions

What is Endo International's stock symbol?

Endo International trades on the NASDAQ under the ticker symbol "ENDP."

How were Endo International's earnings last quarter?

Endo International plc (NASDAQ:ENDP) released its quarterly earnings results on Tuesday, February, 27th. The company reported $0.77 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.62 by $0.15. The company earned $768.64 million during the quarter, compared to analysts' expectations of $762.29 million. Endo International had a negative net margin of 58.68% and a positive return on equity of 81.03%. The business's quarterly revenue was down 38.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.77 earnings per share. View Endo International's Earnings History.

When is Endo International's next earnings date?

Endo International is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Endo International.

What guidance has Endo International issued on next quarter's earnings?

Endo International updated its FY18 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of $2.15-2.55 for the period, compared to the Thomson Reuters consensus estimate of $2.86. The company issued revenue guidance of $2.6-2.8 billion, compared to the consensus revenue estimate of $3.03 billion.

What price target have analysts set for ENDP?

20 Wall Street analysts have issued 1-year price objectives for Endo International's shares. Their predictions range from $7.00 to $16.00. On average, they anticipate Endo International's share price to reach $9.4063 in the next year. View Analyst Ratings for Endo International.

What are Wall Street analysts saying about Endo International stock?

Here are some recent quotes from research analysts about Endo International stock:
  • 1. Cantor Fitzgerald analysts commented, "Takeaways from the quarter: 1) Executing well against its stated objectives in U.S. generics, during 4Q17, the U.S. generics segment launched six products and submitted two regulatory filings. In 2017, the U.S. generics segment launched 17 products and ENDP made 12 regulatory submissions. As of 12/31/17, ENDP had ~100 ANDAs (~1/3 FTF/FTM) pending with the FDA. 2) Sterile Injectables is a growing franchise. Sterile Injectables revenue increased 16% YOY. This increase was driven by Adrenalin. 3) Important sterile injectable drugs include Vasostrict and Adrenalin. ENDP reported 2017 Vasostrict sales of $400MM and Adrenalin sales of $77MM. 4) As of 12/31/17, ENDP had $987MM in unrestricted cash, net debt of ~$7.3B and a net leverage ratio of 4.6x. 5) 4Q17 cash provided by operating activities was $132MM, compared to $84MM of net cash provided by operating activities in 2016. 6) Cellulite could be a big opportunity for ENDP. RELEASE-1 And RELEASE-2 Phase 3 trials looking at Xiaflex for the treatment cellulite were initiated. Topline data are expected 1Q19. ENDP plans to submit all the data in 2019. ENDP expects to commercialize the product on its own, but would consider strategic alternatives. 7) ENDP thinks that the generic market seems more stable, but it is still early in 2018." (2/27/2018)
  • 2. According to Zacks Investment Research, "While Endo's Sterile Injectables and Branded Specialty products business units continue to perform well, the decline in generics industry persist thereby impacting the company's top-line. The branded pharmaceuticals business contiinues to be impacted by continued generic competition for established products, product divestitures and ceasing shipments of Opana ER. The business is expected to decline further as the year progresses. Endo withdrew opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA’s request in June. The drug represented 4% of total 2016 revenues. The company divested its non-core assets such as Belbuca and restructured its pain franchise to focus particularly on specialty branded business. Shares have underperformed the indutsry in the past one year." (1/15/2018)
  • 3. Mizuho analysts commented, "We Lower PT to $12 from $14; Buy on Valuation Rating Buy Previous Rating No Change Price (1/02) $8.10 Price Target $12.00 Previous Price Target $14.00 Summary We reiterate our Buy rating but lower our PT to $12 from $14. We think 2018 guidance may prove disappointing, but we continue to view the stock as undervalued." (1/3/2018)

Are investors shorting Endo International?

Endo International saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 36,160,124 shares, an increase of 10.5% from the March 15th total of 32,726,829 shares. Based on an average daily trading volume, of 5,015,686 shares, the days-to-cover ratio is presently 7.2 days. Approximately 18.1% of the company's shares are sold short.

Who are some of Endo International's key competitors?

Who are Endo International's key executives?

Endo International's management team includes the folowing people:
  • Mr. Paul V. Campanelli, CEO, Pres & Director (Age 56)
  • Mr. Blaise Coleman, Exec. VP & CFO (Age 44)
  • Mr. Terrance J. Coughlin, Exec. VP & COO (Age 52)
  • Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 46)
  • Mr. Daniel A. Rudio, Chief Accounting Officer, Sr. VP & Controller

Has Endo International been receiving favorable news coverage?

News coverage about ENDP stock has trended somewhat positive on Tuesday, according to Accern Sentiment. The research group rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Endo International earned a news sentiment score of 0.14 on Accern's scale. They also assigned media coverage about the company an impact score of 45.28 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Endo International?

Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endo International's stock price today?

One share of ENDP stock can currently be purchased for approximately $5.65.

How big of a company is Endo International?

Endo International has a market capitalization of $1.23 billion and generates $3.47 billion in revenue each year. The company earns $-2,035,430,000.00 in net income (profit) each year or $3.84 on an earnings per share basis. Endo International employs 3,039 workers across the globe.

How can I contact Endo International?

Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]


MarketBeat Community Rating for Endo International (ENDP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  667 (Vote Outperform)
Underperform Votes:  616 (Vote Underperform)
Total Votes:  1,283
MarketBeat's community ratings are surveys of what our community members think about Endo International and other stocks. Vote "Outperform" if you believe ENDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENDP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Endo International (NASDAQ:ENDP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
20 Wall Street analysts have issued ratings and price targets for Endo International in the last 12 months. Their average twelve-month price target is $9.4063, suggesting that the stock has a possible upside of 66.48%. The high price target for ENDP is $16.00 and the low price target for ENDP is $7.00. There are currently 1 sell rating, 16 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.102.152.212.15
Ratings Breakdown: 1 Sell Rating(s)
16 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
15 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
13 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
15 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.4063$9.7188$10.9688$12.8824
Price Target Upside: 66.48% upside39.24% upside35.92% upside68.62% upside

Endo International (NASDAQ:ENDP) Consensus Price Target History

Price Target History for Endo International (NASDAQ:ENDP)

Endo International (NASDAQ:ENDP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2018MizuhoDowngradeBuy -> Neutral$12.00 -> $7.00HighView Rating Details
3/10/2018BarclaysSet Price TargetHold$9.00LowView Rating Details
3/5/2018BMO Capital MarketsLower Price TargetMarket Perform -> Market Perform$10.00 -> $9.00HighView Rating Details
2/28/2018GabelliDowngradeBuy -> HoldHighView Rating Details
2/27/2018OppenheimerReiterated RatingHoldHighView Rating Details
2/27/2018Canaccord GenuitySet Price TargetHold$7.00HighView Rating Details
2/27/2018Cantor FitzgeraldSet Price TargetHold$7.00LowView Rating Details
2/26/2018JMP SecuritiesDowngradeOutperform -> Market PerformLowView Rating Details
2/14/2018B. RileyInitiated CoverageBuy -> Buy$10.00HighView Rating Details
1/2/2018Leerink SwannInitiated CoverageOutperform -> Outperform$12.00HighView Rating Details
12/12/2017GuggenheimInitiated CoverageNeutral -> Neutral$8.50LowView Rating Details
11/10/2017Piper JaffrayReiterated RatingHold$7.00N/AView Rating Details
11/10/2017CitigroupLower Price TargetNeutral$9.00 -> $7.00N/AView Rating Details
11/10/2017Royal Bank of CanadaLower Price TargetSector Perform -> Sector Perform$9.00 -> $8.00N/AView Rating Details
9/28/2017Goldman SachsInitiated CoverageSell -> Sell$7.00HighView Rating Details
8/10/2017Morgan StanleyLower Price TargetEqual Weight$12.00 -> $8.00LowView Rating Details
8/10/2017CowenReiterated RatingHold$16.00HighView Rating Details
8/9/2017Deutsche BankSet Price TargetBuy$15.00 -> $13.00LowView Rating Details
6/14/2017William BlairReiterated RatingMarket PerformLowView Rating Details
6/9/2017Stifel NicolausDowngradeBuy -> Hold$22.00 -> $15.00HighView Rating Details
1/31/2017Susquehanna BancsharesUpgradeNeutral -> PositiveN/AView Rating Details
1/20/2017JPMorgan ChaseDowngradeOverweight -> Neutral$20.00N/AView Rating Details
9/29/2016Northland SecuritiesUpgradeMarket Perform -> Outperform$27.00N/AView Rating Details
8/9/2016UBSReiterated RatingBuy$30.00N/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Endo International (NASDAQ:ENDP) Earnings History and Estimates Chart

Earnings by Quarter for Endo International (NASDAQ:ENDP)

Endo International (NASDAQ:ENDP) Earnings Estimates

2018 EPS Consensus Estimate: $2.38
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.54$0.59$0.56
Q2 20183$0.59$0.62$0.60
Q3 20183$0.56$0.61$0.59
Q4 20183$0.60$0.64$0.62

Endo International (NASDAQ ENDP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018$0.55N/AView Earnings Details
2/27/2018Before Market$0.62$0.77$762.29 million$768.64 millionViewListenView Earnings Details
11/9/2017Q3$0.85$0.91$794.93 million$786.90 millionViewN/AView Earnings Details
8/8/20176/30/2017$0.74$0.93$832.66 million$875.73 millionViewListenView Earnings Details
5/9/2017Q1 17$1.10$1.23$1.0235 billion$1.0380 billionViewListenView Earnings Details
2/28/2017Q416$1.63$1.77$1.17 billion$1.2420 billionViewListenView Earnings Details
11/8/2016Q316$0.81$1.01$862.47 million$894.30 millionViewListenView Earnings Details
8/8/2016Q216$0.74$0.86$873.50 million$921.00 millionViewListenView Earnings Details
5/5/2016Q116$1.04$1.08$960.96 million$963.54 millionViewListenView Earnings Details
2/29/2016Q415$1.27$1.36$1.07 billion$1.07 billionViewListenView Earnings Details
11/5/2015Q315$1.00$1.02$736.16 million$746.00 millionViewListenView Earnings Details
8/10/2015Q215$1.02$1.08$727.45 million$735.00 millionViewListenView Earnings Details
5/11/2015Q115$1.07$1.17$714.42 million$714.00 millionViewListenView Earnings Details
3/2/2015Q414$1.13$1.16$780.44 million$800.00 millionViewListenView Earnings Details
11/5/2014Q314$0.99$1.15$721.11 million$764.00 millionViewListenView Earnings Details
7/31/2014Q214$0.90$1.06$644.60 million$719.00 millionViewListenView Earnings Details
5/1/2014Q114$0.84$0.92$608.86 million$595.00 millionViewListenView Earnings Details
2/28/2014Q413$0.93$0.96$620.90 million$584.95 millionViewListenView Earnings Details
11/7/2013Q313$1.11$1.34$695.63 million$715.00 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.15$1.42$721.01 million$766.51 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.08$1.09$737.79 million$709.00 millionViewListenView Earnings Details
2/28/2013Q4 2012$1.54$1.62$807.98 million$801.06 millionViewListenView Earnings Details
11/5/2012Q312$1.26$1.28$788.53 million$750.50 millionViewN/AView Earnings Details
8/7/2012$1.19$1.27ViewN/AView Earnings Details
5/1/2012$0.86$0.87ViewN/AView Earnings Details
2/24/2012$1.32$1.40ViewN/AView Earnings Details
10/27/2011$1.28$1.25ViewN/AView Earnings Details
8/9/2011$1.06$1.05ViewN/AView Earnings Details
4/28/2011$1.00$1.00ViewN/AView Earnings Details
2/28/2011$0.97$1.06ViewN/AView Earnings Details
11/1/2010Q3 2010$0.85$0.87ViewN/AView Earnings Details
7/30/2010Q2 2010$0.80$0.81ViewN/AView Earnings Details
4/30/2010Q1 2010$0.75$0.74ViewN/AView Earnings Details
2/22/2010Q4 2009$0.68$0.81ViewN/AView Earnings Details
10/29/2009Q3 2009$0.64$0.63ViewN/AView Earnings Details
7/30/2009Q2 2009$0.67$0.73ViewN/AView Earnings Details
4/29/2009Q1 2009$0.60$0.67ViewN/AView Earnings Details
2/27/2009Q4 2008$0.59$0.66ViewN/AView Earnings Details
10/30/2008Q3 2008$0.52$0.61ViewN/AView Earnings Details
7/31/2008Q2 2008$0.49$0.57ViewN/AView Earnings Details
4/30/2008Q1 2008$0.47$0.51ViewN/AView Earnings Details
2/22/2008Q4 2007$0.44$0.50ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Endo International (NASDAQ:ENDP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Endo International (NASDAQ ENDP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.50%
Institutional Ownership Percentage: 94.72%
Insider Trading History for Endo International (NASDAQ:ENDP)
Institutional Ownership by Quarter for Endo International (NASDAQ:ENDP)

Endo International (NASDAQ ENDP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/15/2017Blaise ColemanCFOBuy6,500$7.89$51,285.0013,729View SEC Filing  
8/15/2017Matthew Joseph MalettaEVPBuy3,000$8.02$24,060.006,984View SEC Filing  
8/14/2017Paul CampanelliCEOBuy6,500$7.71$50,115.00213,620View SEC Filing  
8/10/2017Terrance J CoughlinCOOBuy20,000$7.70$154,000.00181,369View SEC Filing  
3/16/2017Paul CampanelliCEOBuy2,300$10.72$24,656.00207,120View SEC Filing  
3/9/2017Nancy J. HutsonDirectorSell5,325$10.82$57,616.50View SEC Filing  
11/15/2016Roger H. KimmelDirectorSell14,000$17.38$243,320.00View SEC Filing  
5/11/2016Arthur J HigginsDirectorBuy5,000$13.80$69,000.0050,623View SEC Filing  
5/10/2016Arthur J HigginsDirectorBuy11,000$15.42$169,620.0045,623View SEC Filing  
5/10/2016Paul CampanelliInsiderBuy13,000$15.53$201,890.00201,069View SEC Filing  
3/17/2016William SpenglerDirectorBuy1,000$29.20$29,200.0048,835View SEC Filing  
3/16/2016William SpenglerDirectorBuy1,000$35.24$35,240.0047,835View SEC Filing  
3/14/2016Roger H KimmelDirectorBuy1,125$41.94$47,182.5072,237View SEC Filing  
3/7/2016Matthew Joseph MalettaVPBuy500$44.48$22,240.001,000View SEC Filing  
3/7/2016Silva Rajiv DeCEOBuy2,250$44.50$100,125.00250,705View SEC Filing  
3/1/2016Nancy J. HutsonDirectorSell3,413$42.19$143,994.4739,990View SEC Filing  
11/12/2015Shane CookeDirectorBuy4,000$57.13$228,520.0010,179View SEC Filing  
11/11/2015Michael HyattDirectorSell8,000$55.48$443,840.00251,599View SEC Filing  
11/11/2015Paul CampanelliinsiderBuy2,100$55.69$116,949.0015,367View SEC Filing  
11/11/2015Silva Rajiv DeCEOBuy9,006$55.52$500,013.1213,697View SEC Filing  
11/11/2015Suketu UpadhyayCFOBuy4,450$56.37$250,846.5017,740View SEC Filing  
11/11/2015Susan HallEVPBuy1,000$55.35$55,350.007,515View SEC Filing  
6/16/2015Arthur J HigginsDirectorBuy2,500$81.10$202,750.00View SEC Filing  
4/8/2015Caroline B ManogueVPSell105,562$91.90$9,701,147.80View SEC Filing  
11/14/2014Suketu UpadhyayCFOBuy3,700$66.94$247,678.00View SEC Filing  
8/5/2014Arthur J HigginsDirectorBuy3,500$65.65$229,775.00View SEC Filing  
6/9/2014John DeluccaDirectorSell6,764$68.83$465,566.12View SEC Filing  
5/29/2014Caroline B ManogueVPSell175,033$72.02$12,605,876.66View SEC Filing  
5/1/2014John DeluccaDirectorSell8,094$66.31$536,713.1421,596View SEC Filing  
4/1/2014John DeluccaDirectorSell10,384$68.46$710,888.6421,596View SEC Filing  
3/10/2014Arthur HigginsDirectorBuy5,000$73.00$365,000.005,000View SEC Filing  
3/10/2014Ivan GergelEVPSell75,637$72.47$5,481,413.3927,649View SEC Filing  
8/26/2013Caroline ManogueVPSell145,592$39.40$5,736,324.8046,422View SEC Filing  
8/8/2013Roger KimmelDirectorBuy5,478$36.50$199,947.0051,914View SEC Filing  
4/9/2013Caroline B ManogueVPSell35,000$35.00$1,225,000.00View SEC Filing  
11/12/2012David HolveckCEOBuy7,425$26.84$199,287.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Endo International (NASDAQ ENDP) News Headlines

Source:
DateHeadline
ENDO Arm Gets Health Canada Nod for TreatmentENDO Arm Gets Health Canada Nod for Treatment
www.baystreet.ca - April 23 at 5:18 PM
Paladin Labs Inc. Announces Launch of New Indication for XIAFLEX® (Collagenase Clostridium Histolyticum), Broadening Its Use to the Treatment of Appropriate Patients with Peyronies DiseasePaladin Labs Inc. Announces Launch of New Indication for XIAFLEX® (Collagenase Clostridium Histolyticum), Broadening Its Use to the Treatment of Appropriate Patients with Peyronie's Disease
finance.yahoo.com - April 23 at 8:10 AM
Paladin Labs Announces the Launch of Unisom® Snore Relief, the Only Natural Health Product Throat Spray Available in Canada to Help Relieve Symptoms Associated with SnoringPaladin Labs Announces the Launch of Unisom® Snore Relief, the Only Natural Health Product Throat Spray Available in Canada to Help Relieve Symptoms Associated with Snoring
finance.yahoo.com - April 19 at 8:09 AM
Are Earnings Prospects Improving For Loss-Making Endo International plc’s (NASDAQ:ENDP)?Are Earnings Prospects Improving For Loss-Making Endo International plc’s (NASDAQ:ENDP)?
finance.yahoo.com - April 18 at 5:50 PM
Leerink Swann Analysts Increase Earnings Estimates for Endo International plc (ENDP)Leerink Swann Analysts Increase Earnings Estimates for Endo International plc (ENDP)
www.americanbankingnews.com - April 18 at 8:39 AM
Endo Receives Paragraph IV Notification on VasostrictÂEndo Receives Paragraph IV Notification on VasostrictÂ
www.finanznachrichten.de - April 17 at 6:03 PM
Endo Receives Paragraph IV Notification on Vasostrict®Endo Receives Paragraph IV Notification on Vasostrict®
finance.yahoo.com - April 17 at 6:03 PM
Endo International (ENDP) Upgraded to "Hold" by BidaskClubEndo International (ENDP) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - April 17 at 3:39 PM
Leerink Swann Research Analysts Lower Earnings Estimates for Endo International plc (ENDP)Leerink Swann Research Analysts Lower Earnings Estimates for Endo International plc (ENDP)
www.americanbankingnews.com - April 17 at 6:51 AM
$689.18 Million in Sales Expected for Endo International plc (ENDP) This Quarter$689.18 Million in Sales Expected for Endo International plc (ENDP) This Quarter
www.americanbankingnews.com - April 16 at 3:43 AM
Endo International plc (ENDP) Given Average Rating of "Hold" by BrokeragesEndo International plc (ENDP) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 15 at 3:34 PM
Endo International (ENDP) Downgraded by BidaskClubEndo International (ENDP) Downgraded by BidaskClub
www.americanbankingnews.com - April 14 at 11:26 PM
$0.54 Earnings Per Share Expected for Endo International plc (ENDP) This Quarter$0.54 Earnings Per Share Expected for Endo International plc (ENDP) This Quarter
www.americanbankingnews.com - April 14 at 11:17 AM
Endo to Announce First-Quarter 2018 Financial ResultsEndo to Announce First-Quarter 2018 Financial Results
finance.yahoo.com - April 13 at 8:13 AM
Endo International (ENDP) Stock Rating Lowered by BidaskClubEndo International (ENDP) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 12 at 6:46 PM
Oppenheimer Reaffirms "Hold" Rating for Endo International (ENDP)Oppenheimer Reaffirms "Hold" Rating for Endo International (ENDP)
www.americanbankingnews.com - April 12 at 11:27 AM
Endo International plc (ENDP) Sees Significant Growth in Short InterestEndo International plc (ENDP) Sees Significant Growth in Short Interest
www.americanbankingnews.com - April 12 at 2:18 AM
Endo International (ENDP) Given a $13.00 Price Target by Deutsche Bank AnalystsEndo International (ENDP) Given a $13.00 Price Target by Deutsche Bank Analysts
www.americanbankingnews.com - April 11 at 7:18 PM
Endo International (ENDP) Given a $9.00 Price Target by Royal Bank of Canada AnalystsEndo International (ENDP) Given a $9.00 Price Target by Royal Bank of Canada Analysts
www.americanbankingnews.com - April 11 at 6:13 PM
Update: Endo Pharmaceuticals Will Be Crushed By Opioid LitigationUpdate: Endo Pharmaceuticals Will Be Crushed By Opioid Litigation
seekingalpha.com - April 11 at 5:39 PM
Endo International (ENDP) Stock Rating Reaffirmed by MizuhoEndo International (ENDP) Stock Rating Reaffirmed by Mizuho
www.americanbankingnews.com - April 11 at 5:01 PM
New Research: Key Drivers of Growth for Seagate Technology, AveXis, Banco Latinoamericano de Comercio Exterior, S.A, SunOpta, Orix Corp Ads, and Endo International plc — Factors of Influence, Major Initiatives and Sustained ProductionNew Research: Key Drivers of Growth for Seagate Technology, AveXis, Banco Latinoamericano de Comercio Exterior, S.A, SunOpta, Orix Corp Ads, and Endo International plc — Factors of Influence, Major Initiatives and Sustained Production
finance.yahoo.com - April 9 at 8:12 AM
ValuEngine Upgrades Endo International (ENDP) to "Buy"ValuEngine Upgrades Endo International (ENDP) to "Buy"
www.americanbankingnews.com - April 8 at 12:54 PM
Endo International (ENDP) Rating Lowered to Sell at Zacks Investment ResearchEndo International (ENDP) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 4 at 6:54 PM
Opioid lawsuits stymie an Endo turnaround, Mizuho says in downgradeOpioid lawsuits stymie an Endo turnaround, Mizuho says in downgrade
finance.yahoo.com - April 4 at 4:20 PM
Endo International (ENDP) Stock Rating Lowered by MizuhoEndo International (ENDP) Stock Rating Lowered by Mizuho
www.americanbankingnews.com - April 4 at 8:04 AM
ValuEngine Lowers Endo International (ENDP) to SellValuEngine Lowers Endo International (ENDP) to Sell
www.americanbankingnews.com - April 3 at 4:16 PM
What Falling Estimates & Price Mean for Endo International (ENDP)What Falling Estimates & Price Mean for Endo International (ENDP)
www.zacks.com - April 3 at 8:14 AM
Endo International (ENDP) Agrees to Extend Temporary Stay of FDA LitigationEndo International (ENDP) Agrees to Extend Temporary Stay of FDA Litigation
www.streetinsider.com - April 2 at 5:32 PM
Endo extends temporary stay of FDA litigationEndo extends temporary stay of FDA litigation
seekingalpha.com - April 2 at 5:32 PM
Endo Agrees to Extend Temporary Stay of FDA LitigationEndo Agrees to Extend Temporary Stay of FDA Litigation
finance.yahoo.com - April 2 at 8:26 AM
Endo International (ENDP) Rating Lowered to Hold at ValuEngineEndo International (ENDP) Rating Lowered to Hold at ValuEngine
www.americanbankingnews.com - March 31 at 2:40 PM
Endo International (ENDP) Earns Buy Rating from MizuhoEndo International (ENDP) Earns Buy Rating from Mizuho
www.americanbankingnews.com - March 31 at 12:46 AM
Zacks: Brokerages Expect Endo International plc - (ENDP) Will Post Quarterly Sales of $689.18 MillionZacks: Brokerages Expect Endo International plc - (ENDP) Will Post Quarterly Sales of $689.18 Million
www.americanbankingnews.com - March 30 at 2:48 AM
Arkansas sues opioid manufacturers for roles in epidemicArkansas sues opioid manufacturers for roles in epidemic
finance.yahoo.com - March 29 at 5:35 PM
Why Is Endo International (ENDP) Down 15% Since its Last Earnings Report?Why Is Endo International (ENDP) Down 15% Since its Last Earnings Report?
finance.yahoo.com - March 29 at 5:35 PM
Cantor Fitzgerald Analysts Give Endo International (ENDP) a $7.00 Price TargetCantor Fitzgerald Analysts Give Endo International (ENDP) a $7.00 Price Target
www.americanbankingnews.com - March 28 at 7:06 PM
Endo International plc - (ENDP) Short Interest Up 12.7% in MarchEndo International plc - (ENDP) Short Interest Up 12.7% in March
www.americanbankingnews.com - March 28 at 3:14 AM
At $5.86, Is Endo International plc (NASDAQ:ENDP) A Buy?At $5.86, Is Endo International plc (NASDAQ:ENDP) A Buy?
finance.yahoo.com - March 26 at 5:25 PM
Quotidian Technical Highlights on Selected Drug Makers Stocks -- Depomed, DURECT, Endo, and Ionis PharmaQuotidian Technical Highlights on Selected Drug Makers Stocks -- Depomed, DURECT, Endo, and Ionis Pharma
www.bizjournals.com - March 26 at 8:15 AM
See what the IHS Markit Score report has to say about Endo International PLC.See what the IHS Markit Score report has to say about Endo International PLC.
finance.yahoo.com - March 26 at 8:15 AM
FY2018 EPS Estimates for Endo International plc - Cut by Analyst (ENDP)FY2018 EPS Estimates for Endo International plc - Cut by Analyst (ENDP)
www.americanbankingnews.com - March 26 at 1:27 AM
Endo International (ENDP) Downgraded to "Hold" at ValuEngineEndo International (ENDP) Downgraded to "Hold" at ValuEngine
www.americanbankingnews.com - March 25 at 6:25 PM
Endo Internationals (ENDP) Hold Rating Reaffirmed at OppenheimerEndo International's (ENDP) Hold Rating Reaffirmed at Oppenheimer
www.americanbankingnews.com - March 24 at 6:17 PM
Endo International (ENDP) Raised to Sell at BidaskClubEndo International (ENDP) Raised to Sell at BidaskClub
www.americanbankingnews.com - March 24 at 1:56 PM
Q1 2018 Earnings Forecast for Endo International plc - (ENDP) Issued By B. RileyQ1 2018 Earnings Forecast for Endo International plc - (ENDP) Issued By B. Riley
www.americanbankingnews.com - March 23 at 7:46 AM
Endo International plc - (ENDP) Given Consensus Recommendation of "Hold" by BrokeragesEndo International plc - (ENDP) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 21 at 3:55 PM
Intraday Update: Dow Gains 115 Points Despite Looming Rate HikeIntraday Update: Dow Gains 115 Points Despite Looming Rate Hike
finance.yahoo.com - March 20 at 5:23 PM
Options Traders Expect Huge Moves in Endo International (ENDP) StockOptions Traders Expect Huge Moves in Endo International (ENDP) Stock
finance.yahoo.com - March 19 at 5:23 PM
South Dakota sues opioid makers as litigation swellsSouth Dakota sues opioid makers as litigation swells
finance.yahoo.com - March 14 at 7:14 PM

SEC Filings

Endo International (NASDAQ:ENDP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Endo International (NASDAQ:ENDP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Endo International (NASDAQ ENDP) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.